# Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine

> **NCT05453487** · PHASE4 · UNKNOWN · sponsor: **China National Biotec Group Company Limited** · enrollment: 360 (estimated)

## Conditions studied

- COVID-19
- Rabies

## Interventions

- **BIOLOGICAL:** coadministration
- **BIOLOGICAL:** COVID-19 vaccine
- **BIOLOGICAL:** rabies vaccine

## Key facts

- **NCT ID:** NCT05453487
- **Lead sponsor:** China National Biotec Group Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-21
- **Primary completion:** 2022-10-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2022-07-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05453487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05453487, "Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05453487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*